Wesley Hand
Johns Hopkins University
9 Papers
56 Citations
Wesley Hand is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 5, co-authored 9 publications.
Chat about Author
Papers
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*
Amy E. DeZern,Amer M. Zeidan,John Barnard,Wesley Hand,Najla Al Ali,Francis Brown,Cassie Zimmerman,Gail J. Roboz,Guillermo Garcia-Manero,David P. Steensma,Rami S. Komrokji,Mikkael A. Sekeres +11 more
TL;DR: First-line therapy for higher-risk myelodysplastic syndromes (MDS) includes decitabine (DAC) or azacitidine (AZA) but Variables have not identified differential response rates between these, and the influence of patient sex on outcomes including overall survival is assessed.
Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature
Kelly J. Norsworthy,Amy E. DeZern,Hua Ling Tsai,Wesley Hand,Ravi Varadhan,Steven D. Gore,Steven D. Gore,Ivana Gojo,Keith W. Pratz,Hetty E. Carraway,Hetty E. Carraway,Margaret M. Showel,Michael A. McDevitt,Michael A. McDevitt,Douglas E. Gladstone,Gabriel Ghiaur,Gabrielle T. Prince,Amy Hatfield Seung,Dina J. Benani,Mark J. Levis,Judith E. Karp,B. Douglas Smith +21 more
TL;DR: The results demonstrate the efficacy and feasibility of TST induction for newly diagnosed patients with AML, with results comparable to that seen in clinical trials with other TST therapies and 7+3.
11
Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)
Rami S. Komrokji,Amy E. DeZern,Katrina Zell,Najla Al Ali,Christopher Estling,Cassie Zimmerman,Wesley Hand,Francis Brown,Nicole Rizzo,John Barnard,Gail J. Roboz,Guillermo Garcia-Manero,David P. Steensma,Mikkael A. Sekeres +13 more
TL;DR: The best response by IWG 2006 criteria to first line therapy in higher-risk MDS correlates with OS, while pts who achieved SD or better response had improved outcome compared to PD, with mCR having an OS equivalent to SD.
10
Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs)
Mikkael A. Sekeres,Katrina Zell,John Barnard,Amy E. DeZern,David P. Steensma,Cassie Zimmerman,Christopher Estling,Wesley Hand,Gail J. Roboz,Nicole Rizzo,Najla Al Ali,Alan F. List,Guillermo Garcia-Manero,Jaroslaw P. Maciejewski,Rami S. Komrokji +14 more
TL;DR: The primary endpoint was overall survival (OS) at the time of ESA failure, defined as cessation of treatment due to relapse or refractoriness; a secondary endpoint was time to AML transformation or death, from time of response (for responders) or failure (for nonresponders) determination.
7
Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC)
Rami S. Komrokji,Amy E. DeZern,Katrina Zell,Najla Al Ali,Eric Padron,Christopher Estling,Cassie Zimmerman,Wesley Hand,Francis Brown,Nicole Rizzo,John Barnard,Gail J. Roboz,Hetty E. Carraway,Jaroslaw P. Maciejewski,Alan F. List,Guillermo Garcia-Manero,David P. Steensma,Mikkael A. Sekeres +17 more
TL;DR: SF3B1 somatic mutation in MDS is commonly associated with RS, lower risk disease, and better OS, and biologically rational therapies are needed that target this molecular disease subset.
4